Darling Ingredients and its health brand Rousselot have introduced Nextida NxCogni, which the company calls the first targeted collagen peptide ingredient formulated to support clarity and cognitive resilience. The announcement was made by press release on October 20, 2026.

Collagen peptides are short chains of amino acids produced by breaking down collagen, the structural protein most familiar to supplement buyers from skin and joint products. NxCogni is a non-stimulant powder sold to manufacturers rather than consumers, intended for capsules and tablets in dietary supplements.

What is actually in it

Darling says the composition contains more than 10 neurosupportive peptides at concentrations exceeding 100 times those found in standard hydrolyzed collagen. That is the company's own figure, and the comparison is against generic hydrolyzed collagen rather than against any competing cognitive ingredient.

Jeroen Colpaert, executive vice president at Rousselot, said many products on the market rely on stimulants for a brief energy spike and that NxCogni is built differently, working with the brain's natural pathways rather than acting as a stimulant. He described it as a natural-derived, evidence-based ingredient dedicated to supporting sustained focus and cognitive resilience.

The trials have not happened yet

Here is the part worth sitting with. The release says clinical trials begin with an open-label human study in December 2026, followed by two large-scale randomized controlled trials planned for the first quarter of 2027, and that those results are expected to confirm the ingredient's preclinical research.

So the human data does not exist. Rousselot is showing the ingredient at SupplySide Global in Las Vegas from October 28 to 30 and taking sample requests, two months before the first open-label study starts. The word evidence-based is doing a lot of work in a sentence written before the first participant enrolls.

Why the platform matters commercially

NxCogni follows Nextida GC, the platform's flagship ingredient, which the company says supports the body's natural GLP-1 response to help maintain healthy post-meal blood glucose levels and is patented in the U.S., Europe, China, Japan and Australia. Darling processes about 30% of the world's collagen, gelatin and hydrolyzed collagen combined, so a move to sell targeted compositions rather than commodity powder is the obvious margin play.

The company's own release flags that all of this is forward-looking and that there is no assurance it will realize these expectations. That is boilerplate, but in this case it is also an accurate description of the evidence.

Bottom line

A collagen fraction aimed at cognition is a genuinely interesting idea, and the concentration claim is specific enough to be testable. Whether it holds up is a question for the randomized trials in early 2027, not for the trade show booth this month.